What is PROLIFIC?
PROLIFIC, the Prognostic Lung Fibrosis Consortium, aims to guide and streamline the development of targeted treatment strategies for patients with pulmonary fibrosis. PROLIFIC members include the Pulmonary Fibrosis Foundation, Bristol Myers Squibb, Chiesi USA, Galapagos NV, Galecto, Genentech, Gilead Sciences, Lassen Therapeutics, Lung Therapeutics, Novartis Institutes for BioMedical Research, OptiKira, Pliant Therapeutics, Three Lakes Foundation, and Tvardi Therapeutics.
By developing tests to detect biomarkers in patients, PROLIFIC will study the early indicators of a drug’s activity. With the long term-goal of finding biomarkers that can predict which patients would benefit the most from a particular treatment, PROLIFIC’s efforts will enable physicians to better tailor therapeutic treatments for patients.
The 12 biomarkers include markers of:
- Epithelial damage – CYFRA 21-1, SP-D, CA-19-9, and KL-6
- Fibrosis – MMP-7, tenascin-C, and periostin
- Inflammation – CCL18, CXCL13, slCAM 1
- Thrombosis – PAI-1
Researchers will screen samples from the PFF Registry to identify and validate blood protein biomarkers.